Dr. Chase Beisel is an Assistant Professor at North Carolina State University who was recognized earlier this year with one of Bay Area Lyme Foundation’s prestigious Emerging Leader Awards. This honor is in recognition of and support for his lab‘s novel work exploring CRISPR technology as a potential treatment for Lyme infections.
Dr. Beisel’s work integrates molecular biology, chemical engineering, and mathematical modeling and has been acknowledged with several National Science Foundation (NSF), National Institute for Health (NIH) and other important awards. His foray into the field of Lyme is a new direction for his lab and ties directly to the Foundation’s aim of attracting some of the brightest and best minds in the country to apply innovative new approaches and methodology to accelerate the development of new diagnostics and treatments for Lyme disease. We are excited about his work and asked him to elaborate further in this recent conversation.
Bay Area Lyme Foundation Increases Annual ‘Emerging Leader Award’ Grants to $350,000 for Lyme Disease Research
2017 additional award invites applications from Associate Professors through Full Professors
Silicon Valley, California, October 3, 2016 – Bay Area Lyme Foundation, supporter of research aimed at making Lyme disease easy to diagnose and simple to cure, announced today that it is beginning to accept applications for a new $250,000 grant award that has been added to its existing “Emerging Leader Award” portfolio of yearly funding.Made available to researchers through the generosity of the Steven and Alexandra Cohen Foundation and the Laurel Foundation, the portfolio also includes the $100,000 “Emerging Leader Award” which has previously been granted to researchers from Harvard, Stanford, UCSF, NC State and Louisiana State University.
Philanthropists and Scientists Collaborate to Increase the Pace of Lyme Disease Research, Raising $815,000 at LymeAid 2016
Weekend kicks off with high-level scientific discussions, and concludes with a fun-filled performance by the legendary Diana Ross
Palo Alto, CA (May 3, 2016) – This weekend, Bay Area Lyme Foundation, a leading nonprofit funder and advocate of innovative Lyme disease research in the US, hosted a 2-day event aimed at helping make Lyme disease easy to diagnose and simple to cure.Scientists and clinicians, who met to strategize concepts and collaborations on Saturday, were joined by more than 300 philanthropists, celebrities, patients and others in the medical field for the fourth annual LymeAid on Sunday.The benefit dinner and concert raised more than $815,000, of which 100% will go directly to fund research for Lyme disease.More than 329,000 Americans are diagnosed each year with this potentially debilitating disease.
Diana Ross headlined LymeAid, energizing the enthusiastic crowd with “I Will Survive” and “Ain’t No Mountain High Enough”, whose names offered unique relevance for the audience and brought attendees to their feet for an hour of nonstop dancing. Earlier in the evening two other voices also entertained guests with original songs addressing the need to overcome this devastating disease.Kiva, 11, movingly performed his original song “10 Years and 17 Doctors” about his mother’s struggle with Lyme disease.Additionally, Sony/ATV singer/songwriter Dana Parish, who dealt with great difficulty being diagnosed and treated for Lyme disease, performed “Pull You Through”.
Bay Area Lyme Foundation Announces Grant Application for Two $100,000 Awards for Lyme Disease Research
‘Emerging Leader Award’ aims to attract new scientific talent to address scientific challenges of Lyme disease
Silicon Valley, California, October 5, 2015—The Bay Area Lyme Foundation, a leading national funder of Lyme disease research in the US, today announced a call for applications for two $100,000 Bay Area Lyme Foundation ‘Emerging Leader Award’ grants.These awards will be given to two promising scientists who embody the future of leadership in Lyme disease research in the US.The award recipients will be researchers in academia or the private sector who are currently at the post-doctoral level through the assistant Professor level, or equivalent, who have identified a defined approach to improve diagnostics or therapies for Lyme disease. Important criteria include demonstrated professional and scientific leadership in the biomedical sciences and a strong supporting scientific rationale for the project.Research efforts funded by the award are required to generate initial proof of concept within 12–18 months.
Why is it that Lyme disease is so little understood, so hard to diagnose, and so frustratingly difficult to get treated? Such were the questions discussed last night at the first of the new Bay Area Lyme Foundation Speaker Series talks.
2014 Emerging Leader Award recipient Jerome Bouquet, PhD, UCSF, began the program with a compelling overview of the history of Lyme disease and its pathology, highlighting some of the complicated attributes of the Lyme-causing spirochete and the manifestations of its infection. He touched on promising new technologies like the Tick Chip and the IBIS-developed Iridica, which use unbiased DNA amplification and multiplex assays with greater sensitivity (and more immediate results) than traditional methods. He also described promising developments in transcriptomics that have illustrated the lingering effects of the disease up to six months after treatment, and
Bay Area Lyme Foundation Awards Grant to Harvard Medical School Researchers for Development of an Accurate Test for Lyme Disease
2015 Emerging Leader Award Seeks to Accelerate Scientific Solutions for Lyme Disease
PORTOLA VALLEY, CA — Bay Area Lyme Foundation, the leading national nonprofit funder of innovative Lyme disease research, today announced that the winners of its 2015 Emerging Leader Award, are collaborators Nira Pollock, MD, PhD, and John Branda, MD. The $100,000 grant that accompanies this award will support their research on a potential biomarker for Lyme disease, which may lead to the development of a novel urine test for early Lyme disease. The most commonly used diagnostic for Lyme disease, the two-tier serological ELISA/Western Blot process, misses up to 60% of cases of early stage Lyme.
Lisa Blum is an enterprising young scientist and postdoctoral fellow at Stanford University School of Medicine, working in the lab of Dr. Bill Robinson. Earlier this year she was recognized as a Bay Area Lyme Foundation Emerging Leader and received a $100,000 project grant. Here she talks about her research, life at Stanford, and the impact of the award.
Q: Earlier this year, your project, “Sequencing of Antibody Responses to Borrelia burgdorferi Infection — Generation of Recombinant Antibodies with Diagnostic and Therapeutic Utility” helped earn you recognition as a Bay Area Lyme Emerging Leader.Tell us about your project and what you hope to accomplish.
Antibodies are proteins produced by the immune system that protect us from infections, but in some cases the antibodies themselves can damage the human body. Our goal is to characterize antibodies produced during different stages of Lyme disease, and to generate monoclonal antibodies that can be used to improve on existing Lyme disease treatments and diagnosis.